Timing and efficacy of alternative methods of sympathetic blockade

Current Hypertension Reports

Volumn 14, Issue 5, 2012, Pages 455-461

  Briasoulis, Alexandros ^a   Bakris, George L ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Alternative therapies; Antihypertensive drugs; Baroreflex activation therapy; BAT; Blood pressure; Hypertension; Invasive treatment; Renal injury; Renal sympathetic denervation; Resistant hypertension; RSD; Sympathetic activation

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; CLONIDINE; METHYLDOPA; MOXONIDINE; NORADRENALIN;

BAROREFLEX ACTIVATION THERAPY; BLOOD PRESSURE REGULATION; BRADYCARDIA; CLINICAL TRIAL (TOPIC); COMPUTER PROGRAM; CONGESTIVE HEART FAILURE; DIASTOLIC BLOOD PRESSURE; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; ELECTROSTIMULATION THERAPY; EQUIPMENT DESIGN; HEART BLOCK; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DENERVATION; KIDNEY DISEASE; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; PATIENT SAFETY; PATIENT SELECTION; PRESSORECEPTOR REFLEX; PULSE GENERATOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR UPREGULATION; RENAL SYMPATHETIC DENERVATION THERAPY; REVIEW; SEDATION; SIDE EFFECT; SYMPATHETIC BLOCKING; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNITED STATES; XEROSTOMIA;

ANTIHYPERTENSIVE AGENTS; BAROREFLEX; CAROTID SINUS; ELECTRIC STIMULATION THERAPY; HUMANS; HYPERTENSION; KIDNEY; PRESSORECEPTORS; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84870549347     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0294-3     Document Type: Review

References (41)

1. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982;62:347-504.
2. Abboud FM. Integration of reflex responses in the control of blood pressure and vascular resistance. Am J Cardiol. 1979;44:903-11.
3. Grassi G, Seravalle G, Quarti-Trevano F, et al. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension. 2009;53:205-9.
4. Huggett RJ, Scott EM, Gilbey SG, et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108:3097-101.
5. Sun C, Zubcevic J, Polson JW, et al. Shift to an involvement of phosphatidylinositol 3-kinase in angiotensin II actions on nucleus tractus solitarii neurons of the spontaneously hypertensive rat. Circ Res. 2009;105:1248-55.
6. Hausberg M, Kosch M, Harmelinck P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974-9.
7. Holmer S, Rinne B, Eckardt KU, et al. Role of renal nerves for the expression of renin in adult rat kidney. Am J Physiol. 1994;266:F 738-45.
8. Katholi RE, Hageman GR, Whitlow PL, et al. Hemodynamic and afferent renal nerve responses to intrarenal adenosine in the dog. Hypertension. 1983;5(Supp I):I-149-54.
9. Katholi RE, Whitlow PL, Hageman GR, et al. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens. 1984;2:349-59.
10. Griffith L, Schwartz S. Reversal of renal hypertension by electrical stimulation of the carotid sinus nerve. Surgery. 1964;56:232-6.
11. Ernsberger P, Giuliano R, Willette RN, Granata AR, Reis DJ. Hypotensive action of clonidine analogues correlates with binding affinity at imidazole and not alpha-2-adrenergic receptors in the rostral ventrolateral medulla. J Hypertens Suppl. 1988;6:S554-7.
12. Kuppers H, Jager B, Luszick J, et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens. 1997;15:93-7.
13. Pocock S, Wilhelmsen L, Dickstein K, Francis G, Wittes J. The data monitoring experience in the MOXCON trial. Eur Heart J. 2004;25:1974-8.
14. Lohmeier TE, Hildebrandt DA, Warren S, et al. Recent insights into the interactions between the baroreflex and the kidneys in hypertension. Am J Physiol Regul Integr Comp Physiol. 2005;288: R828-36.
15. McCubbin J, Green J, Page I. Baroreceptor function in chronic renal hypertension. Clin Res. 1956;4:205-10.
16. Chapleau MW, Hajduczok G, Abboud FM. Mechanisms of resetting of arterial baroreceptors: an overview. Am J Med Sci. 1988;295:327-34.
17. Bristow JD, Honour AJ, Pickering GW, et al. Diminished baroreflex sensitivity in high blood pressure. Circulation. 1969;39:48-54.
18. Lohmeier TE, Irwin ED, Rossing MA, et al. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension. 2004;43:306-11.
19. Lohmeier TE, Dwyer TM, Irwin ED, et al. Prolonged activation of the baroreflex abolishes obesity-induced hypertension. Hypertension. 2007;49:1307-14.
20. Lohmeier TE, Iliescu R, Dwyer TM, et al. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex. Am J Physiol Heart Circ Physiol. 2010;299:H402-9. This study of BAT in hypertensive dogs showed that chronic activation of the carotid baroreflex reduced the blood pressure and heart rate. The induced reductions were not diminished by adaptations in the brain and peripheral circulation.
21. Lohmeier TE, Hildebrandt DA, Dwyer TM, et al. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension. 2007;49:373-9.
22. Lohmeier TE, Dwyer TM, Hildebrandt DA, et al. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension. 2005;46:1194-200.
23. Lohmeier TE, Hildebrandt DA, Dwyer TM, et al. Prolonged activation of the baroreflex decreases arterial pressure even during chronic adrenergic blockade. Hypertension. 2009;53:833-8.
24. Bilgutay A, Lillehei W. Surgical treatment of hypertension with reference to baropacing. Am J Cardiol. 1966;17:663-7.
25. Tuckman J, Reichman T, Lyon A, et al. Electrical stimulation of the sinus nerves in hypertensive patients: clinical evaluation and physiological studies. Hypertension. 1967;194S:23-8.
26. Scheffers I, Kroon AA, Tordoir J, et al. Rheos Baroreflex Hypertension Therapy System to treat resistant hypertension. Expert Rev Med Devices. 2008;5:33-9.
27. Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006;44:123-1218.
28. Bisognano J, Sloand J, Papademetriou V, et al. An implantable carotid sinus baroreflex activating system for drug-resistant hypertension: interim chronic efficacy results from the multicenter Rheos Feasibility Trial. Circulation. 2006;114(18 Suppl):II575.
29. Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56:1254-8.
30. Wustmann K, Kucera JP, Scheffers I, et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension. 2009;54:530-6.
31. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial. J Am Coll Cardiol. 2011;58:765-73. The trial sought to determine the effect of baroreflex activation therapy (BAT) on systolic blood pressure (SBP) in patients with resistant hypertension. It demonstrated significant benefit for the endpoints of sustained efficacy, BAT safety and device safety.
32. Bakris GL, Nadim MK, Haller H, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6(2):152-8.
33. Katholi RE. Renal nerves in the pathogenesis of hypertension in experimental animals and humans. Am J Physiol. 1983;245:F1-14.
34. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatmentofhypertension; reviewof122 cases.Lancet. 1953;1:403-8.
35. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: amulticentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-81.
36. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet. 2010;376:1903-9. This study was designed to assess the effectiveness and safety of catheter-based renal denervation for reduction of blood pressure in patients with treatment-resistant hypertension. Catheter-based renal denervation can safely be used to substantially reduce blood pressure in treatment-resistant hypertensive patients.
37. Ukena C, Mahfoud F, Kindermann I, et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2011; 58(11):1176-82.
38. Symplicity HTN-3 Investigators. Renal denervation in patients with uncontrolled hypertension (SYMPLICITY HTN-3). ClinicalTrials.-gov NCT01418261.
39. Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN-3 Trial. Clin.Cardiol. 2012. doi: 10.1002/clc.22008.
40. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559-65.
41. Brandt MC, Mahfoud F, Reda S. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59 (10):901-9.